IDEXX LABORATORIES, INC.

(IDXX)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
372.23 USD   +2.03%
05/19Goldman Sachs Adjusts IDEXX Laboratories' Price Target to $530 From $615, Maintains Neutral Rating
MT
05/18IDEXX Laboratories to Present at Stifel Conference and Announces 2022 Investor Day
PR
05/13IDEXX LABORATORIES INC /DE : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PetDx and IDEXX Expand Access to OncoK9, the Cancer Liquid Biopsy Test for Dogs

01/13/2022 | 09:01am EDT

SAN DIEGO, Jan. 13, 2022 /PRNewswire/ -- PetDx® – The Liquid Biopsy Company for Pets™, dedicated to unleashing the power of genomics to improve pet health, announced today a collaboration with IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, to significantly broaden access to canine cancer liquid biopsy testing. 

OncoK9®, PetDx's pioneering liquid biopsy test for the detection of cancer in dogs, will be available later this month to all veterinary customers, in the United States and Canada, served by IDEXX Reference Laboratories.

"We are excited about IDEXX's support of our noninvasive cancer testing solutions," said PetDx Chief Operating Officer Kalle Marsal. "Working closely with the industry leader will accelerate our efforts to equip the market with this breakthrough innovation, and ultimately benefit many dogs, their families, and the veterinarians that manage their care."

Launched in 2021, OncoK9 is the first and only liquid biopsy test for the detection of cancer-associated genomic alterations in dogs. Employing cutting-edge genomic analysis, OncoK9 leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms to offer new cancer-detection capabilities that empower veterinarians to provide superior care to canine patients. This collaboration will expedite access to this groundbreaking test that can be easily incorporated into the veterinary clinical routine with a simple blood draw.

Cancer is by far the leading cause of death in dogs, with an estimated six million new cancer diagnoses made each year in the U.S. population of approximately 90 million pet dogs. In the CANDiD (CANcer Detection in Dogs) Study, which enrolled more than 1,000 dogs, OncoK9 demonstrated the ability to detect cancer with sensitivity and specificity performance mirroring that of liquid biopsy tests recently developed for cancer screening in human patients. Results of this clinical validation study have been submitted for publication to a leading peer-reviewed journal, and are summarized in a white paper on the PetDx website.

PetDx and IDEXX are both exhibitors at the VMX conference; they can be found in the expo hall at the Orange County Convention Center in Orlando, Fla, Jan. 15-19, 2022. 

About PetDx
PetDx® – The Liquid Biopsy Company for Pets™ is a San Diego-based molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health. The company's flagship product, OncoK9®, enables veterinarians to detect cancer in dogs with a simple blood draw. As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms empowering veterinarians to provide superior care to canine patients. To learn more, visit www.petdx.com.

Contact: petdx@teamlewis.com

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/petdx-and-idexx-expand-access-to-oncok9-the-cancer-liquid-biopsy-test-for-dogs-301459809.html

SOURCE PetDx


© PRNewswire 2022
All news about IDEXX LABORATORIES, INC.
05/19Goldman Sachs Adjusts IDEXX Laboratories' Price Target to $530 From $615, Maintains Neu..
MT
05/18IDEXX Laboratories to Present at Stifel Conference and Announces 2022 Investor Day
PR
05/13IDEXX LABORATORIES INC /DE : Submission of Matters to a Vote of Security Holders (form 8-K..
AQ
05/05JPMorgan Adjusts Price Target for IDEXX Laboratories to $625 From $725, Maintains Overw..
MT
05/05Morgan Stanley Adjusts IDEXX Laboratories' Price Target to $603 from $732, Keeps Overwe..
MT
05/05BofA Securities Downgrades IDEXX Laboratories to Neutral From Buy, Adjusts Price Target..
MT
05/04IDEXX LABORATORIES INC /DE Management's Discussion and Analysis of Financial Condition..
AQ
05/04SECTOR UPDATE : Health Care Stocks Climb Pre-Bell Wednesday
MT
05/04TRANSCRIPT : IDEXX Laboratories, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04IDEXX Laboratories Q1 Earnings Slide, Revenue Rises; Company Lowers 2022 Outlook
MT
More news
Analyst Recommendations on IDEXX LABORATORIES, INC.
More recommendations